Plasma concentration of big endothelin-1 and its relation with plasma NT-proBNP and ventricular function in heart failure patients;Relación de los valores plasmáticos de big endotelina-1 con Nt-proBNP y la función ventricular de pacientes con insuficiencia cardíaca

Revista Espanola de Cardiologia

Volumn 58, Issue 3, 2005, Pages 278-284

  Rivera Otero, J Miguel ^a   Cortés, Raquel ^a   Portolés, Manuel ^a   Valero, Ricardo ^b   Sancho Tello, María J ^a   Martínez Dolz, Luis ^a   Sevilla, Begoña ^c   Taléns Visconti, Raquel ^a   Jordán, Alejandro ^d   Miró, Vicente ^a   Pérez Boscá, José L ^e   Marín, Francisco ^f   Climent, Vicente ^f   García de Burgos, Fernando ^d   Payá, Rafael ^e   Sogorb, Francisco ^f   Bertomeu, Vicente ^b   Salvador, Antonio ^c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Big endothelin 1; Heart failure; Natriuretic peptides; Ventricular function

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 20244381985     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072475     Document Type: Article

References (40)

1. Sigurdsson A, Swedberg K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am Heart J. 1996;132:229-34.
2. Sigurdsson A, Amtorp O, Gundersen T, Nilsson B, Remes J, Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J. 1994;72:422-7.
3. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002;106:92-9.
4. Eriksson SV, Eneroth P, Kjekshus J, Offstad J, Swedberg K. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin Cardiol. 1994;17:603-6.
5. Roig E. Utilidad clínica de los marcadores neurohormonales en la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:347-56.
6. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293-9.
7. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-9.
8. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation. 1994;89:1580-6.
9. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27: 633-41.
10. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-5.
11. Levin ER. Endothelins. N Engl J Med. 1995;333:356-63.
12. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415.
13. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6: 261-8.
14. Salomone A. Los péptidos natriuréticos en la insuficiencia cardíaca: mejorando el diagnóstico y el manejo del síndrome. Rev Esp Cardiol. 2002;55:4-6.
15. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
16. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-53.
17. Rivera M, Taléns-Visconti R, Salvador A, Bertomeu V, Miró V, García de Burgos F, et al. Hipertensión y valores de NT-proBNP. Su importancia en el diagnóstico de insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:396-402
18. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287-96.
19. Winquist RJ, Scott AL, Vlasuk GP. Enhanced release of atrial natriuretic factor by endothelin in atria from hypertensive rats. Hypertension. 1989;14:111-4.
20. Thibault G, Doubell AF, García R, Lariviere R, Schiffrin EL. Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors. Circ Res. 1994;74:460-70.
21. Saijonmaa O, Ristimaki A, Fyhrquist F. Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Commun. 1990;173:514-20.
22. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Kurihara N, et al. Atrial and brain natriuretic peptides: secretion during exercise in patients with essential hypertension and modulation by acute angiotensin-converting enzyme inhibition. Clin Exp Pharmacol Physiol. 1992;19:193-200.
23. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic, peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest. 1991; 87:1999-2004.
24. Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. Rev Cardiovasc Med. 2003;4 Suppl 4:29-36.
25. Valdivieso A. The kidney in chronic liver disease: circulatory abnormalities, renal sodium handling and role of natriuretic peptides. Biol Res. 1998;31:291-304.
26. Carrillo-Jiménez R, Lamas GA, Henneken CH. Plasma levels of brain natriuretic peptide: a potential marker for HIV-related cardiomyopathy. J Cardiovasc Pharmacol Ther. 2002;7:135-7.
27. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev. 2003;8:355-8.
28. Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2004;170:360-5.
29. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-8.
30. Remme WJ. Towards the better treatment of heart failure. Eur Heart J. 1998;19 Suppl L:36-42.
31. García MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32:865-75.
32. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-67.
33. Willenheimer R, Israelsson B, Cline C, Rydberg E, Broms K, Erhardt L. Left atrioventricular plane displacement is related to both systolic and diastolic left ventricular performance in patients with chronic heart failure. Eur Heart J. 1999;20:612-8.
34. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail. 2004;6:365-8.
35. Kinugawa T, Kato M, Ogino K, Osaki S, Igawa O, Hisatome I, et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail. 2003;9:318-24.
36. Yamamoto T, Kimura T, Ota K, Shoji M, Inoue M, Sato K, et al. Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. Am J Physiol. 1992;262: E856-62.
37. Rivera M, Cortés R, Mora V, Miró V, Cosín J, Jordán A, et al. NT-proBNP y desplazamiento del plano auriculoventricular. Relación e implicaciones diagnósticas. Rev Esp Cardiol. 2003;56: 1043-9.
38. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002;90:435-8.
39. Stangl K, Dschietzig T, Richter C, Laule M, Stangl V, Tanis E, et al. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation. 2000;102: 1132-8.
40. Eicken A, Fratz S, Gutfried C, Balling G, Schwaiger M, Lange R, et al. Hearts late after fontan operation have normal mass, normal volume, and reduced systolic function: a magnetic resonance imaging study. J Am Coll Cardiol. 2003;42(6):1061-5.